Page last updated: 2024-08-24

fenofibric acid and Insulin Sensitivity

fenofibric acid has been researched along with Insulin Sensitivity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Mikhailidis, DP; Wierzbicki, AS; Wray, R	1
Ide, T; Kobayashi, N; Murakami, K; Nagasawa, M; Tsunoda, M; Utsumi, M	1
Chew, GT; Sahebkar, A; Watts, GF	1

Reviews

2 review(s) available for fenofibric acid and Insulin Sensitivity

Article	Year
Drug treatment of combined hyperlipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2001, Volume: 1, Issue:5 Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver Diseases; Obesity; Pancreatitis; Pregnancy; Pregnancy Complications	2001
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4 Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides	2014

Article

Year

Drug treatment of combined hyperlipidemia.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2001, Volume: 1, Issue:5

Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver Diseases; Obesity; Pancreatitis; Pregnancy; Pregnancy Complications

2001

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.

Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4

Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides

2014

Other Studies

1 other study(ies) available for fenofibric acid and Insulin Sensitivity

Article	Year
A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. American journal of physiology. Endocrinology and metabolism, 2008, Volume: 294, Issue:5 Topics: Adiponectin; Adipose Tissue; Animals; Butyrates; Dietary Fats; DNA, Complementary; Dogs; Dose-Response Relationship, Drug; Fatty Acids; Fenofibrate; Genes, Reporter; Humans; Hypolipidemic Agents; Insulin Resistance; Lipids; Liver; Luciferases; Male; Obesity; Oxidation-Reduction; PPAR alpha; PPAR delta; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation	2008

Article

Year

A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.

American journal of physiology. Endocrinology and metabolism, 2008, Volume: 294, Issue:5

Topics: Adiponectin; Adipose Tissue; Animals; Butyrates; Dietary Fats; DNA, Complementary; Dogs; Dose-Response Relationship, Drug; Fatty Acids; Fenofibrate; Genes, Reporter; Humans; Hypolipidemic Agents; Insulin Resistance; Lipids; Liver; Luciferases; Male; Obesity; Oxidation-Reduction; PPAR alpha; PPAR delta; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation

2008